Regeneron basks in first gene therapy approval as Dupixent, Eylea carry robust Q1 earnings

Regeneron hauled in $3.6 billion during the first quarter of 2026, as analysts homed in on a slight Eylea HD miss and key upcoming readouts, including for LAG3 candidate fianlimab in metastatic melanoma.